Anderson Carryn, Kim Richard
Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.
Cancer Treat Rev. 2009 Jun;35(4):322-7. doi: 10.1016/j.ctrv.2008.11.009. Epub 2009 Jan 14.
Cholangiocarcinoma is a rare neoplasm originating from the intra- or extrahepatic bile duct epithelium. Incidence has been increasing worldwide in the last three decades. Complete surgical resection provides the only possibility of cure, but even with resection 5-yr survival can be as low as 11%. Adjuvant therapy has the potential to play a crucial role in prolonging survival and local control. Retrospective series have suggested benefit to adjuvant radiation, chemotherapy or concurrent chemo-radiation. The scarce prospective data has not shown a survival benefit to adjuvant therapy. In this article we review and summarize the published data regarding adjuvant therapy for resected extrahepatic cholangiocarcinoma. Prospective, multi-institutional randomized trials are needed to clarify the role of adjuvant therapy in this disease.
胆管癌是一种起源于肝内或肝外胆管上皮的罕见肿瘤。在过去三十年中，全球发病率一直在上升。完整的手术切除是唯一可能治愈的方法，但即使进行了切除，5年生存率也可能低至11%。辅助治疗在延长生存期和局部控制方面可能发挥关键作用。回顾性系列研究表明辅助放疗、化疗或同步放化疗有益。稀缺的前瞻性数据并未显示辅助治疗对生存有益。在本文中，我们回顾并总结了已发表的关于切除的肝外胆管癌辅助治疗的数据。需要进行前瞻性、多机构随机试验来阐明辅助治疗在这种疾病中的作用。
